• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

钠-葡萄糖协同转运蛋白2抑制剂在肾小球疾病治疗中的争议

Sodium glucose co-transporter 2 inhibitors in the treatment of glomerular diseases: a controversy.

作者信息

Caravaca-Fontán Fernando, Del Vecchio Lucia, Praga Manuel, Floege Jürgen, Zoccali Carmine

机构信息

Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain.

Department of Nephrology and Dialysis, ASST Lariana, Como, Italy.

出版信息

Clin Kidney J. 2024 Aug 12;17(9):sfae237. doi: 10.1093/ckj/sfae237. eCollection 2024 Sep.

DOI:10.1093/ckj/sfae237
PMID:39228996
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11367167/
Abstract

Integrating sodium-glucose co-transporter 2 inhibitors (SGLT2i) into the treatment for chronic kidney disease (CKD) has marked a significant therapeutic advance in nephrology. Clinical trials such as DAPA-CKD and EMPA-KIDNEY have demonstrated the beneficial effects of SGLT2i in slowing CKD progression and reducing proteinuria. However, the applicability of these results to patients with glomerulonephritis is still unresolved due to various limitations. This manuscript combines the evidence supporting the use of SGLT2i in glomerular diseases, highlights the limitations and strikes a conclusive balance on their role in clinical practice.

摘要

将钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）纳入慢性肾脏病（CKD）治疗已标志着肾脏病学领域的一项重大治疗进展。诸如DAPA-CKD和EMPA-KIDNEY等临床试验已证明SGLT2i在延缓CKD进展和减少蛋白尿方面的有益作用。然而，由于各种局限性，这些结果在肾小球肾炎患者中的适用性仍未得到解决。本手稿综合了支持在肾小球疾病中使用SGLT2i的证据，强调了局限性，并就其在临床实践中的作用达成了结论性的平衡。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3bd/11367167/5955aca89b78/sfae237fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3bd/11367167/a0c906255184/sfae237fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3bd/11367167/5955aca89b78/sfae237fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3bd/11367167/a0c906255184/sfae237fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3bd/11367167/5955aca89b78/sfae237fig2.jpg

相似文献

1
Sodium glucose co-transporter 2 inhibitors in the treatment of glomerular diseases: a controversy.钠-葡萄糖协同转运蛋白2抑制剂在肾小球疾病治疗中的争议
Clin Kidney J. 2024 Aug 12;17(9):sfae237. doi: 10.1093/ckj/sfae237. eCollection 2024 Sep.
2
SGLT2 Inhibitors in the Management of Chronic Kidney Disease: An Expert Consensus.SGLT2 抑制剂在慢性肾脏病管理中的应用：专家共识。
J Assoc Physicians India. 2022 Oct;70(10):11-12. doi: 10.5005/japi-11001-0122.
3
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence.钠-葡萄糖协同转运蛋白2抑制剂在非糖尿病慢性肾脏病患者中的疗效与安全性：近期证据综述
Kidney Dis (Basel). 2023 Apr 11;9(5):326-341. doi: 10.1159/000530395. eCollection 2023 Oct.
4
Renal Protection and Safety of Sodium-glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.钠-葡萄糖共转运蛋白 2 抑制剂在慢性肾脏病中的肾脏保护和安全性。
Curr Pharm Des. 2023;29(21):1659-1670. doi: 10.2174/1381612829666230804103643.
5
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na/H exchanger, lowering of cytosolic Na and vasodilation.SGLT2 抑制剂在小鼠心肌细胞和心脏中的类效应：抑制 Na/H 交换器，降低细胞溶质 Na 并扩张血管。
Diabetologia. 2018 Mar;61(3):722-726. doi: 10.1007/s00125-017-4509-7. Epub 2017 Dec 2.
6
Expectations in children with glomerular diseases from SGLT2 inhibitors.肾小球疾病患儿对 SGLT2 抑制剂的期待。
Pediatr Nephrol. 2022 Dec;37(12):2997-3008. doi: 10.1007/s00467-022-05504-6. Epub 2022 Mar 14.
7
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis.钠-葡萄糖共转运蛋白 2 抑制剂在原发性和继发性肾小球肾炎中的应用。
Nephrol Dial Transplant. 2024 Jan 31;39(2):328-340. doi: 10.1093/ndt/gfad175.
8
Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus.达格列净对无糖尿病的慢性肾脏病患者初始估算肾小球滤过率下降的影响。
Clin Exp Nephrol. 2023 Jan;27(1):44-53. doi: 10.1007/s10157-022-02277-y. Epub 2022 Sep 17.
9
Seven suggestions for successful SGLT2i use in glomerular disease - a standalone CKD therapy?在肾小球疾病中成功使用 SGLT2i 的七点建议 - 一种独立的 CKD 疗法？
Curr Opin Nephrol Hypertens. 2022 May 1;31(3):272-277. doi: 10.1097/MNH.0000000000000786. Epub 2022 Feb 25.
10
Nephroprotection by SGLT2i in CKD Patients: May It Be Modulated by Low-Protein Plant-Based Diets?SGLT2抑制剂对慢性肾脏病患者的肾脏保护作用：是否会受到低蛋白植物性饮食的调节？
Front Med (Lausanne). 2020 Dec 3;7:622593. doi: 10.3389/fmed.2020.622593. eCollection 2020.

引用本文的文献

1
SGLT2 Inhibitors in Glomerulonephritis: Beyond Nephroprotection?肾小球肾炎中的SGLT2抑制剂：超越肾脏保护作用？
J Clin Med. 2025 May 18;14(10):3533. doi: 10.3390/jcm14103533.
2
The Effects of SGLT2 Inhibitors on Lipid Profile and Kidney Function in Patients with Chronic Kidney Disease Regardless of Diabetes and Hypertension Status.无论糖尿病和高血压状况如何，SGLT2抑制剂对慢性肾脏病患者脂质谱和肾功能的影响
Metabolites. 2025 Apr 13;15(4):271. doi: 10.3390/metabo15040271.

本文引用的文献

1
Drugs in Development to Treat IgA Nephropathy.治疗 IgA 肾病的在研药物。
Drugs. 2024 May;84(5):503-525. doi: 10.1007/s40265-024-02036-1. Epub 2024 May 23.
2
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.原发性肾脏疾病对恩格列净治疗慢性肾脏病患者疗效的影响：EMPA-KIDNEY 试验的二次分析。
Lancet Diabetes Endocrinol. 2024 Jan;12(1):51-60. doi: 10.1016/S2213-8587(23)00322-4. Epub 2023 Dec 4.
3
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis.
钠-葡萄糖共转运蛋白 2 抑制剂在原发性和继发性肾小球肾炎中的应用。
Nephrol Dial Transplant. 2024 Jan 31;39(2):328-340. doi: 10.1093/ndt/gfad175.
4
SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy.SGLT2 抑制剂通过减少炎症和增强自噬来减轻狼疮肾炎中的足细胞损伤。
Ann Rheum Dis. 2023 Oct;82(10):1328-1340. doi: 10.1136/ard-2023-224242. Epub 2023 Jul 24.
5
Safety of SGLT2 inhibitors in patients with different glomerular diseases treated with immunosuppressive therapies.不同肾小球疾病患者接受免疫抑制治疗时 SGLT2 抑制剂的安全性。
Eur J Clin Pharmacol. 2023 Jul;79(7):961-966. doi: 10.1007/s00228-023-03508-1. Epub 2023 May 18.
6
Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system.恩格列净的肾保护作用与其激活管球反馈机制和抑制补体系统有关。
Am J Physiol Cell Physiol. 2023 Apr 1;324(4):C951-C962. doi: 10.1152/ajpcell.00528.2022. Epub 2023 Feb 13.
7
Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial.SGLT2 抑制剂达格列净在系统性红斑狼疮患者中的安全性和疗效：一项 I/II 期试验。
RMD Open. 2022 Oct;8(2). doi: 10.1136/rmdopen-2022-002686.
8
Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.达格列净、依普利酮及其联合应用对慢性肾脏病患者蛋白尿降低作用的随机交叉临床试验。
J Am Soc Nephrol. 2022 Aug;33(8):1569-1580. doi: 10.1681/ASN.2022020207. Epub 2022 Apr 19.
9
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.钠-葡萄糖协同转运蛋白2抑制剂与2型糖尿病患者高钾血症风险：来自随机对照试验的个体参与者数据的荟萃分析
Circulation. 2022 May 10;145(19):1460-1470. doi: 10.1161/CIRCULATIONAHA.121.057736. Epub 2022 Apr 8.
10
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.达格列净治疗局灶节段性肾小球硬化症患者的安全性和疗效：达格列净和慢性肾脏病结局预防（DAPA-CKD）试验的预先指定分析。
Nephrol Dial Transplant. 2022 Aug 22;37(9):1647-1656. doi: 10.1093/ndt/gfab335.